Health Check is renowned biotech journo Tim Boreham’s daily wrap covering morning movers and shakers of note in the ASX ...

A spokesperson for Advanz told pharmaphorum that, at the moment, the company does not have a timeline for when a ... Another potential option is Gilead Sciences PPAR agonist Livdelzi (seladelpar ...

GENEVA, 2 October 2024—Responding to today’s announcement by Gilead on lenacapavir ... HIV medicines at scale if the drugs are affordable and if there’s a clear timeline as to when the drugs will be ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Gilead Sciences (GILD) ended the recent trading session at $85.83, demonstrating a +0.91% swing from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.76%.

AstraZeneca, the UK’s largest drugmaker valued at $140bn, has reportedly contacted Gilead Sciences, an American biopharmaceutical company with a market value of approximately $96bn, regarding a ...